相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy
Thomas G. von Lueder et al.
CIRCULATION-HEART FAILURE (2015)
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
Milton Packer et al.
CIRCULATION (2015)
Telmisartan Exerts Sustained Blood Pressure Control and Reduces Blood Pressure Variability in Metabolic Syndrome by Inhibiting Sympathetic Activity
Daisuke Sueta et al.
AMERICAN JOURNAL OF HYPERTENSION (2014)
Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696
Pardeep S. Jhund et al.
CIRCULATION-HEART FAILURE (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Renin-Angiotensin Blockade Combined With Natriuretic Peptide System Augmentation Novel Therapeutic Concepts to Combat Heart Failure
Thomas G. von Lueder et al.
CIRCULATION-HEART FAILURE (2013)
First-in-Class Angiotensin Receptor Neprilysin Inhibitor in Heart Failure
O. Vardeny et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Novel Mechanism for Disrupted Circadian Blood Pressure Rhythm in a Rat Model of Metabolic Syndrome-The Critical Role of Angiotensin II
Daisuke Sueta et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Amlodipine Enhances Amelioration of Vascular Insulin Resistance, Oxidative Stress, and Metabolic Disorders by Candesartan in Metabolic Syndrome Rats
Daisuke Sueta et al.
AMERICAN JOURNAL OF HYPERTENSION (2012)
Comparative Risk for Angioedema Associated With the Use of Drugs That Target the Renin-Angiotensin-Aldosterone System
Sengwee Toh et al.
ARCHIVES OF INTERNAL MEDICINE (2012)
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
Scott D. Solomon et al.
LANCET (2012)
Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat
Laxminarayan G. Hegde et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2011)
Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)
Jessie Gu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
Luis Miguel Ruilope et al.
LANCET (2010)
Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema
R. M. Fryer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Molecular biology of the natriuretic peptide system - Implications for physiology and hypertension
David G. Gardner et al.
HYPERTENSION (2007)
Biology of natriuretic peptides and their receptors
KN Pandey
PEPTIDES (2005)
Angioedema associated with angiotensin-converting enzyme inhibitor use - Outcome after switching to a different treatment
M Cicardi et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Omapatrilat and enalapril in patients with hypertension: The omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial
OB Kostis et al.
AMERICAN JOURNAL OF HYPERTENSION (2004)
Vasopeptidase inhibition - A double-edged sword?
DJ Campbell
HYPERTENSION (2003)
分享论文
